An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Altimmune, Inc. (Nasdaq: ALT) will be represented by Dr. Scott Harris, Chief Medical Officer, at two upcoming conferences: BTIG Obesity Health Forum and GLP-1-Based Therapeutics Summit. The presentations will focus on emerging therapeutics and the use of GLP-1s in treating MASH & Fatty Liver Disease.
Altimmune, Inc. (Nasdaq: ALT) sarà rappresentata dal Dr. Scott Harris, Direttore Medico, in due prossime conferenze: il BTIG Obesity Health Forum e il GLP-1-Based Therapeutics Summit. Le presentazioni si concentreranno su terapie emergenti e sull'uso dei GLP-1 nel trattamento della MASH e della Malattia del Fegato Grasso.
Altimmune, Inc. (Nasdaq: ALT) estará representada por el Dr. Scott Harris, Jefe de Medicina, en dos próximas conferencias: el Foro de Salud sobre Obesidad de BTIG y la Cumbre de Terapéuticas Basadas en GLP-1. Las presentaciones se enfocarán en terapias emergentes y el uso de los GLP-1 en el tratamiento de la enfermedad MASH y la Enfermedad del Hígado Graso.
Altimmune, Inc. (Nasdaq: ALT)는 최고의료책임자인 스콧 해리스 박사가 참여하는 두 개의 다가오는 컨퍼런스, BTIG 비만 건강 포럼과 GLP-1 기반 치료 정상회의에서 대표될 것입니다. 이 발표들은 신흥 치료법과 MASH 및 지방간 질환 치료에 GLP-1 사용에 중점을 둘 것입니다.
Altimmune, Inc. (Nasdaq: ALT) sera représentée par le Dr. Scott Harris, Directeur Médical, lors de deux conférences à venir : le Forum sur la Santé et l'Obésité de BTIG et le Sommet sur les Thérapeutiques Basées sur les GLP-1. Les présentations se concentreront sur les nouvelles thérapies et l'utilisation des GLP-1 dans le traitement de la MASH et de la Maladie du Foie Gras.
Altimmune, Inc. (Nasdaq: ALT) wird von Dr. Scott Harris, dem Chefarzt, auf zwei bevorstehenden Konferenzen vertreten sein: dem BTIG Obesity Health Forum und dem GLP-1-Based Therapeutics Summit. Die Präsentationen werden sich auf neue Therapien und den Einsatz von GLP-1s in der Behandlung von MASH und Fettleberkrankheit konzentrieren.
Positive
None.
Negative
None.
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present on behalf of the Company at the following two upcoming conferences:
BTIG Obesity Health Forum (Virtual Conference) Title: Emerging Therapeutics Panel Wednesday, May 8, 2024 Panel Discussion at 4:00 pm Eastern Time
Title: Focusing on the Use of GLP-1s in Treating MASH & Fatty Liver Disease Wednesday, May 15, 2024 Presentation at 10:00 am Eastern Time
Title: Attaining Product Differentiation through Improved Patient Segmentation & Efficiency Thursday, May 16, 2024 Presentation at 1:30pm Eastern Time
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on Twitter
When and where will Altimmune participate in upcoming conferences?
Altimmune, Inc. (Nasdaq: ALT) will participate in the BTIG Obesity Health Forum on May 8, 2024, and the GLP-1-Based Therapeutics Summit on May 15 and May 16, 2024.
Who will represent Altimmune at the conferences?
Dr. Scott Harris, Chief Medical Officer at Altimmune, will represent the company at the upcoming conferences.
What will be the focus of Altimmune's presentations at the conferences?
The presentations will focus on emerging therapeutics and the use of GLP-1s in treating MASH & Fatty Liver Disease.
altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current
